Views Expressed Disclaimer:

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. 

Highlights

  • Trellus Health shares climb 111.11% on 18 February 2026, despite a 51.28% decline over the past year.
  • Six-month contract extension with Johnson & Johnson validates platform performance.
  • Trellus Elevate continues supporting patients with moderate to severe inflammatory bowel disease.
  • TrialSet deployment progresses with ICON plc and PSI Inc. across multiple clinical trials.
  • Monthly cash burn reduced to USD 400,000, supported by recurring management fees.
  • GBP 5 million convertible facility secured to extend cash runway into late Q1 2026.

Trellus Health PLC (LSE:TRLS) shares surged 111.11% to GBX 0.95 during the morning session on 18 February 2026, although the stock remains down 51.28% over the past year. The sharp rise follows the announcement of a major contract extension with Johnson & Johnson and reflects growing investor confidence in the Company’s digital health platform and expanding clinical trial initiatives.

Johnson & Johnson Partnership Strengthens

Trellus Health has secured a six-month extension of its collaboration with Johnson & Johnson Health Care Systems. Initially launched in January 2025, this extension maintains the same economic terms, including a fixed monthly management fee, reflecting the favourable engagement and satisfaction metrics achieved during the pilot phase.

As part of the agreement, access channels for patients receiving J&J therapies have been expanded, offering them enhanced tools and support to manage the physical and emotional challenges of moderate to severely active inflammatory bowel disease.

The contract extension underscores the growing confidence of a major pharmaceutical partner in Trellus Elevate and its ability to drive patient adherence and engagement outcomes. This collaboration forms a cornerstone of the Company’s strategic focus on recurring revenue and scalable digital health solutions.

Clinical Trial Expansion and Operational Progress

Beyond its commercial partnership, Trellus Health continues to advance its TrialSet vertical. Deployment with ICON plc is underway for an ongoing mid-stage immunology and inflammation clinical trial sponsored by Takeda, while PSI Inc. is implementing the platform across two late-stage trials sponsored by Sanofi, with site deployments planned for mid-Q2 2026.

CEO and Co-founder Dr. Marla Dubinsky highlighted that the combined progress of Trellus Elevate and TrialSet positions the Company across the full programme lifecycle, from clinical development to commercial deployment. This integrated model allows Trellus to deliver consistent engagement outcomes while scaling its go-to-market capabilities within the pharmaceutical sector.

Financial Position and Future Plans

Trellus Health reported revenue of approximately USD 545,000 for the year ended 2025, with monthly cash burn reduced to around USD 400,000 by late 2025.

 The Company has secured a GBP 5 million convertible facility with Alumni Capital LLC, with net proceeds from initial tranches extending the cash runway into late Q1 2026. Management continues discussions on additional funding sources to further strengthen liquidity.

The Board remains focused on accelerating commercial momentum through strategic partnerships, deepening pharmaceutical collaborations, and expanding TrialSet adoption across multiple sponsors.

The Johnson & Johnson contract extension, together with ongoing clinical trial implementations, reinforces Trellus Health’s path toward growing recurring revenue and operational visibility throughout 2026.

FAQs

Q1: Why did Trellus Health shares jump over 111% on 18 February 2026?
A1: The surge follows a six-month contract extension with Johnson & Johnson and progress in clinical trial deployments, boosting investor confidence.

Q2: What does the Johnson & Johnson extension mean for Trellus Health?
A2: It validates the Trellus Elevate platform, expands patient access, and supports recurring revenue through ongoing engagement and management fees.

Q3: How is Trellus Health managing its finances in 2026?
A3: Monthly cash burn has been reduced to c. USD 400,000, with a GBP 5 million convertible facility extending the cash runway, and discussions ongoing for further funding.